Valeant prices $1B debt offering; U.K.'s Cameron wants to reduce regulation of drug industry; Flu vax coming up way short on effectiveness;

@FiercePharma: Boehringer mulls sale of generic plant as stateside shakeup continues. More | Follow @FiercePharma

@CarlyHFierce: With Rytary approval in the bag, Impax Labs scouts buyouts in CNS, generics. Article | Follow @CarlyHFierce

> Valeant Pharmaceuticals ($VRX) has priced its $1 billion debt offering at 5.50% with senior unsecured notes due 2023. Report

> Kite Pharma ($KITE) CEO Arie Belldegrun says payer pushback for Gilead Sciences' ($GILD) hep C treatments is helping the company determine how to price the expensive cancer immunotherapy it has under development. Story

> U.K. Prime Minister David Cameron says the current process of developing and licensing new drugs as "abhorrently expensive and time consuming," and will push for lighter regulations on the pharmaceutical industry in order to get drugs to market more quickly. Story

> The U.S. Centers for Disease Control and Prevention says flu vaccines are turning out to be effective in fewer than a quarter of those who have taken them. Story

Medical Device News

@FierceMedDev: FDA, CDC investigating death, illnesses from IV bags intended for training. News | Follow @FierceMedDev

@VarunSaxena2: J&J says fishy phone calls recruiting women to file vaginal mesh-related suits warrant an investigation. More | Follow @VarunSaxena2

@EmilyWFierce: Gilead blazes ahead in hep C pricing battle with two new PBM deals. Report | Follow @EmilyWFierce

> Bill introduced in Congress to simplify marketing of research use only devices and diagnostics. Story

> Medical device, diagnostic venture investment at $2.7B, highest since 2008. More

Biotech News

@FierceBiotech: J&J gets $116M to help hustle along new Ebola vaccine. Article | Follow @FierceBiotech

@JohnCFierce: We are slowly ramping up Asia reporting this month ahead of FiercePharmaAsia launch in Feb. Good time to start sending embargoed news my way. | Follow @JohnCFierce

@DamianFierce: $ENTA gets $50M for EU approval of $ABBV's hep C combo. From #JPM15, here's what they're going to do with it. More | Follow @DamianFierce

> Playing catch-up, Pfizer looks to leapfrog Big Pharma's immuno-oncology line. Article

> J&J gets $116M to help hustle along new Ebola vaccine. More

> UCB taps Neuropore in a $480M Parkinson's collaboration. Story

Suggested Articles

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.

Eli Lilly and Boehringer's Jardiance fell short in a heart failure trial in patients with or without diabetes—a test AZ's rival Farxiga recently aced.